What half-life means
The biological half-life of a peptide is the time required for its concentration in a biological system (typically plasma, in animal models) to fall by 50%. It is not the time until the peptide is completely gone - it takes multiple half-lives to reach negligible levels. After one half-life, 50% remains. After two, 25%. After three, 12.5%. Practical elimination takes five or more half-lives.
Half-life is distinct from duration of effect. A peptide may still produce downstream biological effects after the peptide itself has been cleared, because the signalling cascades it triggered can persist independently.
Why peptide half-lives tend to be short
Most naturally occurring peptides have short half-lives - often minutes to a few hours. Several mechanisms contribute:
Proteolytic degradation: Peptidases in the blood and tissues cleave peptide bonds. Enzymes like dipeptidyl peptidase-4 (DPP-4) specifically target short peptide sequences. GLP-1, for example, has a native plasma half-life of roughly 2 minutes because DPP-4 cleaves it rapidly.
Renal filtration: Small peptides below roughly 50 kDa are filtered by the kidneys and excreted in urine. The smaller the peptide, the faster this occurs.
Receptor-mediated internalization: After binding and activating a receptor, some peptide-receptor complexes are internalized by the cell, removing both the receptor and the bound peptide from circulation.
How research peptides are engineered for longer half-life
Much of modern peptide drug development focuses on extending half-life to make compounds more practical. Common strategies include:
Fatty acid conjugation: Attaching a fatty acid chain to the peptide allows it to bind albumin in the blood, which is too large to be renally filtered. Semaglutide uses this approach to achieve a half-life of approximately one week.
PEGylation: Attaching polyethylene glycol (PEG) chains to the peptide increases its molecular size and reduces renal clearance.
Amino acid substitution: Replacing natural amino acids with non-natural versions (D-amino acids, N-methyl amino acids) at positions targeted by proteases makes the peptide resistant to degradation without necessarily changing its receptor binding.
Cyclic structures: Constraining the peptide into a ring shape can protect vulnerable sites from proteolytic access.
Half-life in research design
Understanding a peptide's half-life is essential for interpreting research. Dosing intervals in animal studies are designed around half-life - a peptide with a 30-minute half-life may need to be administered multiple times per day to maintain consistent exposure, whereas one with a multi-day half-life may be administered weekly.
Results comparing two peptides with different half-lives must account for the difference in exposure. A peptide that appears more potent in a single-dose study may simply have a longer half-life, not a stronger binding affinity.
References: Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006.
What half-life means
The biological half-life of a peptide is the time required for its concentration in a biological system (typically plasma, in animal models) to fall by 50%. It is not the time until the peptide is completely gone - it takes multiple half-lives to reach negligible levels. After one half-life, 50% remains. After two, 25%. After three, 12.5%. Practical elimination takes five or more half-lives.
Half-life is distinct from duration of effect. A peptide may still produce downstream biological effects after the peptide itself has been cleared, because the signalling cascades it triggered can persist independently.
Why peptide half-lives tend to be short
Most naturally occurring peptides have short half-lives - often minutes to a few hours. Several mechanisms contribute:
Proteolytic degradation: Peptidases in the blood and tissues cleave peptide bonds. Enzymes like dipeptidyl peptidase-4 (DPP-4) specifically target short peptide sequences. GLP-1, for example, has a native plasma half-life of roughly 2 minutes because DPP-4 cleaves it rapidly.
Renal filtration: Small peptides below roughly 50 kDa are filtered by the kidneys and excreted in urine. The smaller the peptide, the faster this occurs.
Receptor-mediated internalization: After binding and activating a receptor, some peptide-receptor complexes are internalized by the cell, removing both the receptor and the bound peptide from circulation.
How research peptides are engineered for longer half-life
Much of modern peptide drug development focuses on extending half-life to make compounds more practical. Common strategies include:
Fatty acid conjugation: Attaching a fatty acid chain to the peptide allows it to bind albumin in the blood, which is too large to be renally filtered. Semaglutide uses this approach to achieve a half-life of approximately one week.
PEGylation: Attaching polyethylene glycol (PEG) chains to the peptide increases its molecular size and reduces renal clearance.
Amino acid substitution: Replacing natural amino acids with non-natural versions (D-amino acids, N-methyl amino acids) at positions targeted by proteases makes the peptide resistant to degradation without necessarily changing its receptor binding.
Cyclic structures: Constraining the peptide into a ring shape can protect vulnerable sites from proteolytic access.
Half-life in research design
Understanding a peptide's half-life is essential for interpreting research. Dosing intervals in animal studies are designed around half-life - a peptide with a 30-minute half-life may need to be administered multiple times per day to maintain consistent exposure, whereas one with a multi-day half-life may be administered weekly.
Results comparing two peptides with different half-lives must account for the difference in exposure. A peptide that appears more potent in a single-dose study may simply have a longer half-life, not a stronger binding affinity.
References: Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006.
